{"Title":"BioXcel Therapeutics","Industry":"PHARMACEUTICAL PREPARATIONS","Employees":"4","Founded":"","Address":"","Phone":"(203) 643-8060","Web_address":"http://www.bioxceltherapeutics.com","Market_cup":"$172.1mil","Revenues":"$0 mil (last 12 months)","Net_income":"$-4.5 mil (last 12 months)","Symbol":"BTAI","Exchange":"NASDAQ","Shares":"5.5","Price_range":"$11.00 - $11.00","Est_volume":"$60.0 mil","Manager":"Barclays/ UBS Investment Bank/ BMO Capital Markets","CO_managers":"Canaccord Genuity","Exp_to_trade":"3/8/2018","Status":"","Quiet_period":"Available only to Subscribers","Lock_up_period":"Available only to Subscribers","Scoop_rate":"Available only to Subscribers","Rating_change":"Available only to Subscribers","Business":"BioXcel Therapeutics,Â Inc., or BTI, is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology. Our drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. We believe that this differentiated approach has the potential to reduce the cost and time of drug development in diseases with substantial unmet medical need."}